aid: carrick-therapeutics
accessModel:
  pricing: unknown
  onboarding: unknown
  trial: false
  try_now: false
  public: false
  label: Unknown
  confidence: low
  source: []
  generated: '2026-07-22'
  method: derived
image: https://kinlane-images.s3.amazonaws.com/shared/apis-json/icons/carrick-therapeutics.png
name: Carrick Therapeutics
description: 'Carrick Therapeutics is a clinical-stage biopharmaceutical company headquartered
  in Boston, Massachusetts, developing novel oncology therapies aimed at improving outcomes
  for patients with aggressive and treatment-resistant cancers. Its pipeline centers on
  transcriptional CDK inhibition, led by samuraciclib (a CDK7 inhibitor in Phase 2) and
  CT7439 (a CDK12/13 inhibitor in Phase 1), pursued as combination therapies across advanced
  hormone-receptor-positive/HER2-negative breast cancer, prostate cancer, ovarian cancer,
  and additional indications. The company is backed by GV (Google Ventures) and was added
  to the API Evangelist network as a life-sciences company profile; it publishes no developer
  API, SDK, or documentation surface at this time.'
url: https://raw.githubusercontent.com/api-evangelist/carrick-therapeutics/refs/heads/main/apis.yml
x-type: company
x-source: vc-portfolio
x-backed-by:
- gv
x-tier: stub
x-tier-reason: portfolio-lead
specificationVersion: '0.20'
created: '2026-07-17'
modified: '2026-07-18'
tags:
- Company
- Life Sciences
- Biotechnology
- Pharmaceuticals
- Oncology
- Clinical Stage
- Drug Development
apis: []
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
common:
- type: DomainSecurity
  url: security/carrick-therapeutics-domain-security.yml
- type: Website
  url: https://www.carricktherapeutics.com
- type: Blog
  url: https://www.carricktherapeutics.com/news-media/press-releases
- type: PrivacyPolicy
  url: https://www.carricktherapeutics.com/privacy-policy
x-enrichment:
  date: '2026-07-19'
  status: backfilled
  pass: local-v1
  note: backfilled from .gitignore signal + verified work evidence